Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ACTRIMS 2022 | What is the latest progress in gene research in MS?

Lars Alfredsson • 25 Feb 2022
ACTRIMS 2022
Multiple Sclerosis and Related Disorders

Lars Alfredsson, PhD, Karolinska Institutet, Stockholm, Sweden, discusses the latest genetic research into multiple sclerosis (MS), whereby over 200 genetic polymorphisms have been associated with risk of MS and more continue to be identified. This interview took place at the ACTRIMS Forum 2022 in West Palm Beach, Florida.

More from Lars Alfredsson

Epstein-Barr virus as a predominant trigger of multiple sclerosis
1:56
Epstein-Barr virus as a predominant trigger of multiple sclerosis
Lars Alfredsson • 25 Feb 2022
Environmental interactions in multiple sclerosis according to DRB1 hetero-homozygosity
4:10
Environmental interactions in multiple sclerosis according to DRB1 hetero-homozygosity
Lars Alfredsson • 25 Feb 2022
Factors affecting the risk of relapsing- and progressive-onset multiple sclerosis
3:32
Factors affecting the risk of relapsing- and progressive-onset multiple sclerosis
Lars Alfredsson • 25 Feb 2022

Related Videos

What are the key changes introduced in the 2024 revision of the McDonald diagnostic criteria for MS?
6:48
What are the key changes introduced in the 2024 revision of the McDonald diagnostic criteria for MS?
Mar Tintoré • 3 Jul 2026
The emerging role of AI in the diagnosis and management of multiple sclerosis
1:55
The emerging role of AI in the diagnosis and management of multiple sclerosis
Celia Oreja-Guevara • 29 Jun 2026
Ovarian aging and long-term prognosis in women with multiple sclerosis
3:07
Ovarian aging and long-term prognosis in women with multiple sclerosis
Mar Tintoré • 3 Jul 2026
Can selected patients with multiple sclerosis safely discontinue ocrelizumab?
3:15
Can selected patients with multiple sclerosis safely discontinue ocrelizumab?
Franz Felix Konen • 28 Jul 2026

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJNeurology is intended for healthcare professionals